Clinical TrialID 8247
Combination of Intranasal Scopolamine and Sensory Augmentation to Mitigate G-transition Induced Motion Sickness and Enhance Sensorimotor Performance
NCT05886660
Motion Sickness, Space|Motion Sickness|Sea Sickness
Relationship Network
Interactive first-hop connections across herbs, ingredients, formulas, targets, diseases, symptoms, syndromes, evidence, and monographs.
Click a node to open it in a new tab
Trial: 1Ingredient: 1Links: 1
Arranging relationship network...
Record Fields
Scalar fields from the final clinical_trial record.
- Clinical Trial Id
- 8247
- Evidence Id
- 8247
- Core Evidence Id
- 8247
- Source Clinical Trial Id
- 8245
- Herb2 Clinical Trial Id
- HBCT008245
- Nct Id
- NCT05886660
- Title
- Combination of Intranasal Scopolamine and Sensory Augmentation to Mitigate G-transition Induced Motion Sickness and Enhance Sensorimotor Performance
- Status
- Recruiting
- Phase
- Phase 2
- Study Result
- No
- Study Condition
- Motion Sickness, Space|Motion Sickness|Sea Sickness
- Study Type
- Interventional
- Study Design
- Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: DOUBLE (PARTICIPANT, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT
- Intervention
- DRUG: DPI-386 Nasal Gel|DRUG: Placebo Nasal Gel|DRUG: DPI-386 Nasal Gel|DRUG: Placebo Nasal Gel
- Intervention Allocation
- Randomized
- Intervention Model
- Crossover
- Intervention Mask
- Double
- Intervention Purpose
- Treatment
- Gender
- All
- Age
- Adult, Older_Adult
- Enrollment
- 30
- Outcome Measure
- Motion sickness (MS) symptom severity using Pensacola Diagnostic Index (PDI) scale, The PDI scale ranges from 0 to 16 with higher numbers reflecting greater symptom severity (in this study a PDI score of 8 will be used as a motion sickness (MS) endpoint). During each session, the primary motion sickness symptoms will be recorded every minute during the capsule wave motion stimulation through the MS endpoint (PDI score ≥ 8 points) up to 45 min total., 45 minutes
- Sponsor Collaborator
- Repurposed Therapeutics, Inc.|National Aeronautics and Space Administration (NASA)
- Funded By
- INDUSTRY
- Location
- NASA Johnson Space Center Neuroscience Laboratory, Houston, Texas, 77058, United States
- Other Id
- NASA 0354 (Aim 1)
- Start Date
- 2022-01-21
- Primary Completion Date
- 2024-09
- Completion Date
- 2024-09
- First Posted
- 2023-06-02
- Results First Posted
- Last Update Posted
- 2024-05-17
- Study Document
- Study Url
- https://clinicaltrials.gov/study/NCT05886660
- Title Cn
- Title En
- Combination of Intranasal Scopolamine and Sensory Augmentation to Mitigate G-transition Induced Motion Sickness and Enhance Sensorimotor Performance
- Bilingual Status
- semi_complete